据VentureBeat报道，数字病理软件领域的领先提供商Proscia最近宣布，已完成900万美元的C+轮融资。此轮融资由Highline Capital Management和Triangle Peak Partners领投，参与投资的还有Alpha Intelligence Capital、Scale Venture Partners、Hitachi Ventures等现有投资者，使得该轮总融资额达到了4600万美元。
Proscia公司致力于开发和推广AI驱动的病理学云平台，通过其平台，病理学家能够实现病理样本的数字化分析和管理，极大提高了病理诊断的效率和准确性。据悉，此轮融资将主要用于加速Proscia的商业增长，尤其是在生命科学和诊断实验室领域的市场拓展，同时也将进一步推动其人工智能应用程序的开发。
Proscia的人工智能技术在病理学领域具有广泛的应用潜力，不仅可以协助病理学家更快速地做出诊断，还能通过大数据分析助力新药研发和个性化治疗方案的制定。随着数字病理学的不断发展，Proscia的平台有望在医疗诊断和疾病治疗方面发挥越来越重要的作用。
此次融资显示出资本市场对Proscia及其技术的认可，也反映了人工智能在医疗领域，特别是在精准医疗和疾病早期诊断中的巨大发展潜力。未来，Proscia将继续深化其在数字病理学领域的领导地位，推动医疗健康行业的创新与发展。
英语如下：
Certainly, here is the translation in Markdown format:
“`markdown
# “Proscia Secures $9 Million in C+ Round Funding to Accelerate Commercialization of AI Pathology Platform”
Keywords: Proscia, Funding, AI Pathology
### Digital Pathology Software Provider Proscia Completes $9 Million C+ Round Funding
According to VentureBeat, leading digital pathology software provider Proscia has recently announced the completion of a $9 million C+ round of funding. This round of funding was led by Highline Capital Management and Triangle Peak Partners, with participation from existing investors including Alpha Intelligence Capital, Scale Venture Partners, and Hitachi Ventures, bringing the total funding to $46 million.
Proscia is dedicated to the development and promotion of AI-driven pathology cloud platforms, which enable pathologists to digitally analyze and manage pathology samples, significantly improving the efficiency and accuracy of pathological diagnoses. It is understood that the funds raised will primarily be used to accelerate Proscia’s business growth, especially in the life sciences and diagnostic laboratory markets, and will also further drive the development of its artificial intelligence applications.
Proscia’s artificial intelligence technology has broad application potential in the field of pathology, not only assisting pathologists in making faster diagnoses but also supporting drug development and the creation of personalized treatment plans through big data analysis. With the continuous development of digital pathology, Proscia’s platform is expected to play an increasingly important role in medical diagnosis and disease treatment.
This round of funding demonstrates the capital market’s recognition of Proscia and its technology and reflects the tremendous development potential of artificial intelligence in the medical field, especially in precision medicine and early disease diagnosis. In the future, Proscia will continue to deepen its leadership in the field of digital pathology and promote innovation and development in the healthcare industry.
“`
This translation maintains the structured format of the original text in Markdown.
【来源】https://venturebeat.com/ai/proscias-46m-series-c-propels-ai-driven-pathology-into-the-mainstream/
Views: 3